
Academic Journal
Q2Antiviral Therapy
About Antiviral Therapy
Antiviral Therapy is a scholarly journal published by Sage Publications. SCImago 2025 lists it in Q2, with an SJR of 0.836 and H-index of 96.
Coverage: 1996-2025. Research categories: Infectious Diseases (Q2); Pharmacology (Q2); Pharmacology (medical) (Q2).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2024-12-02. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
HIV/AIDS drug development and treatment; HIV Research and Treatment; Hepatitis C virus research; HIV-related health complications and treatments; HIV/AIDS Research and Interventions; Hepatitis B Virus Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Kidney function parameters in South African children living with HIV on antiretroviral therapy
Yanhan Shen, Elliott Y. Huang, Olivia Yin, Stephanie Shiau et al.
2026-10 · DOI: 10.1177/13596535261490958COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial
Jennifer Victory, Melissa Scribani, Amanda Hasuly, Paul Jenkins et al.
2026-08 · DOI: 10.1177/13596535261479944Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study
Nina Pennetzdorfer, Vidula Naik, Jairo Mauricio Montezuma-Rusca, Peter Sklar et al.
2026-08 · DOI: 10.1177/13596535261481194Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series
Chloé Pannecoucke, Nadia Valin, Gilles Peytavin, Sidonie Lambert et al.
2026-06 · DOI: 10.1177/13596535261436877Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review
Efrida, Aziizah Yuza
2026-06 · DOI: 10.1177/13596535261450699It’s about time: The association between abacavir and cardiovascular disease
Jim Young, Patrick R. Lawler, Erica E. M. Moodie, Heiner C. Bucher et al.
2026-04 · DOI: 10.1177/13596535261438178Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe – a physician survey
Alicja Dębska-Ślizień, Milena Todorović Balint, Radovan Vrhovac, Aleksandar Biljić Erski et al.
2026-04 · DOI: 10.1177/13596535261440692Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study
Biagio Pinchera, Ludovica Fusco, Vincenzo Fotticchia, Antonio Riccardo Buonomo et al.
2026-02 · DOI: 10.1177/13596535261444510Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage In silico study
Abeer A. M. Hasb, Gamal A. H. Mekhemer, Peter A. Sidhom, Ahmed Rady et al.
2025-12 · DOI: 10.1177/13596535251405027Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection
Yacine Abed, Chantal Rhéaume, Julie Carbonneau, Nicolas Fortin et al.
2025-12 · DOI: 10.1177/13596535251405300A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants
Ed Gane, Christian Schwabe, Min Wu, Tse-I Lin et al.
2025-12 · DOI: 10.1177/13596535251392955Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report
Emma M. de Koff, Harmen van Andel, Hanna K. de Jong, Anneke J. van der Kooi et al.
2025-10 · DOI: 10.1177/13596535251385624Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor, in healthy Chinese male subjects
Wang Hu, Jiaxiang Ding, Yunqiu Xie, Tonghao Zhang et al.
2025-10 · DOI: 10.1177/13596535251377204Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines
Markus Cornberg, Fabien Zoulim, Robert Gish, Ira M. Jacobson et al.
2025-08 · DOI: 10.1177/13596535251349380Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam
Tran Dieu Thuy, Nguyen Thu Ha, Do Duy Cuong, Le Van Long et al.
2025-06 · DOI: 10.1177/13596535251349054Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1
Sandy Van Hemelryck, Erika Van Landuyt, Sofie Deleu, Lorant Leopold et al.
2025-06 · DOI: 10.1177/13596535251349336The diagnostic significance of the C-reactive protein (CRP) in HIV/TB coinfection: A systematic review and meta-analysis
Ying Gao, Wenjuan Ji, Qiuyan Chen
2025-06 · DOI: 10.1177/13596535251345870Magnolol inhibits viral replication and enhances antiviral immune responses against porcine reproductive and respiratory syndrome virus (PRRSV) in Marc-145 cells
Shun Li, Mingzhan Zhu, Jingfei Deng, Yajuan Li et al.
2025-06 · DOI: 10.1177/13596535251345953A review of photodynamic therapy for the treatment of viral skin diseases
Joanna Bartosińska, Dorota Kowalczuk, Paulina Szczepanik-Kułak, Mirosław Kwaśny et al.
2025-04 · DOI: 10.1177/13596535251331728Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database
Laura Labate, Barbara Rossetti, Chiara Russo, Chiara Cassol et al.
2025-04 · DOI: 10.1177/13596535251317054Reviews
Community Reviews
Version History
October 2, 2026 at 8:40 pm
October 2, 2026